IPP Bureau
Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification
By IPP Bureau - January 09, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107
By IPP Bureau - January 09, 2025
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav
By IPP Bureau - January 09, 2025
Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors
JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health
By IPP Bureau - January 09, 2025
He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)
Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
By IPP Bureau - January 09, 2025
Increases speed to market for drug developers working on nucleic acid therapeutics
GEON Performance Solutions acquires Foster Corporation
By IPP Bureau - January 09, 2025
Acquisition expands high-value medical platform
Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical
By IPP Bureau - January 09, 2025
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments
By IPP Bureau - January 09, 2025
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
ProBioGen expands protein and viral manufacturing to drive continued growth
By IPP Bureau - January 09, 2025
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Lilly to establish new global capability centre in Hyderabad
By IPP Bureau - January 09, 2025
Lilly plans to hire approximately more than 1,000 new highly-skilled team members
HMPV update: States advised to strengthen awareness among masses regarding preventive measures
By IPP Bureau - January 08, 2025
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
Biocon Biologics embarks on a three-stage strategic journey
By IPP Bureau - January 08, 2025
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Ajooni Biotech to raise Rs. 45 crore through convertible warrants
By IPP Bureau - January 08, 2025
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
Caplin Point receives EIR from FDA with Zero 483 observations
By IPP Bureau - January 07, 2025
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease
By IPP Bureau - January 07, 2025
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
